Clinical trial suggests new direction for heavy-smoking head and neck cancer patients

(University of Colorado Anschutz Medical Campus) Phase I results of olaparib with cetuximab and radiation led to 72 percent 2-year survival in 16 patients on trial, compared with an expected 2-year survival rate of about 55 percent for standard-of-care treatment.